PFM Health Sciences, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001442756

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2025 · 55 positions · Total reported value $1.12B · Top-10 concentration 55.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.8% · 24 new · 28 cut · 39 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.9% · vs SPY -7.0% · Prev Value $1.14B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.3% · vs SPY +0.2% · Latest Value $978.49M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2025 13F filing, PFM Health Sciences, LP disclosed 55 equity positions with a combined reported value of $1.12B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.8% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were LLY ($208.93M), THC ($87.87M), MCK ($52.99M). By sector, the heaviest allocations are Health Care 82.1%, Industrials 4.2%. Versus the prior quarter, allocation shifted toward Consumer Staples (+1.4pp), Other (+1.2pp) and away from Health Care (-2.8pp).

Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 48% of names.

The largest new positions opened in Q2 2025 were TEVA ($20.76M), NTRA ($17.11M), COR ($15.98M).

Of the 39 positions fully exited versus the prior quarter, the largest were XLV ($62.74M), VRTX ($61.57M), ELV ($38.37M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • TEVA TEVA PHARMACEUTICAL INDS LTD · $20.76M
  • NTRA NATERA INC · $17.11M
  • COR CENCORA INC · $15.98M
  • MASI MASIMO CORP · $15.89M
  • AKRO AKERO THERAPEUTICS INC · $14.20M
  • HOLX HOLOGIC IN · $13.81M
  • IRTC IRHYTHM HOLDINGS INC · $13.57M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · $12.95M

Fully Exited (vs previous quarter)

  • XLV SELECT SECTOR SPDR TR · prev qtr: $62.74M
  • VRTX VERTEX PHARMACEUTICALS INC · prev qtr: $61.57M
  • ELV ELEVANCE HEALTH INC FORMERLY · prev qtr: $38.37M
  • UHS UNIVERSAL HLTH SVCS INC · prev qtr: $29.22M
  • BDX BECTON DICKINSON & CO · prev qtr: $20.98M
  • IQV IQVIA HLDGS INC · prev qtr: $19.72M
  • SNDX SYNDAX PHARMACEUTICALS INC · prev qtr: $11.38M
  • AZN ASTRAZENECA PLC · prev qtr: $11.04M

Insider Transactions (Form 4)

Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-69012 (status: Approved), registered 2008-04-10
  • Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 2 hedge funds
  • Website: pfmhealthsciences.com

Portfolio Structure

  • 96 positions · $1.14B reported value (Q2 2026)
  • Top 10 holdings = 34.6% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
  • Average position size: $11.89M

Sector Tilt

  • Health Care 92.9%
  • Industrials 5.1%
  • Consumer Staples 1.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 32 new, 24 added, 40 reduced, 14 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 82.1%
Other 10.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 268.02K $208.93M 18.72%
18.72%
Reduce
2 499.24K $87.87M 7.87%
7.87%
Add
3 72.31K $52.99M 4.75%
4.75%
Reduce
4 483.11K $50.43M 4.52%
4.52%
Reduce
5 88.97K $48.35M 4.33%
4.33%
Reduce
6 166.26K $42.67M 3.82%
3.82%
Hold
7 407.20K $34.12M 3.06%
3.06%
Reduce
8 479.00K $33.04M 2.96%
2.96%
Add
9 1.66M $31.98M 2.87%
2.87%
Reduce
10 161.41K $31.89M 2.86%
2.86%
Add
11 392.50K $30.70M 2.75%
2.75%
Add
12 23.00M $28.84M 2.58%
2.58%
Hold
13 72.29K $27.69M 2.48%
2.48%
Reduce
14 109.51K $26.77M 2.40%
2.40%
Add
15 85.74K $25.54M 2.29%
2.29%
Add
16 72.22K $23.55M 2.11%
2.11%
Reduce
17 521.79K $22.53M 2.02%
2.02%
Reduce
18 1.24M $20.76M 1.86%
1.86%
New
19 1.36M $19.99M 1.79%
1.79%
Add
20 101.25K $17.11M 1.53%
1.53%
New
21 53.29K $15.98M 1.43%
1.43%
New
22 94.45K $15.89M 1.42%
1.42%
New
23 735.03K $15.76M 1.41%
1.41%
Reduce
24 43.09K $15.04M 1.35%
1.35%
Reduce
25 266.17K $14.20M 1.27%
1.27%
New
26 211.99K $13.81M 1.24%
1.24%
New
27 88.16K $13.57M 1.22%
1.22%
New
28 923.38K $12.95M 1.16%
1.16%
New
29 88.18K $12.83M 1.15%
1.15%
Add
30 34.62K $10.80M 0.97%
0.97%
Reduce
31 17.13K $10.58M 0.95%
0.95%
New
32 36.39K $10.46M 0.94%
0.94%
New
33 178.32K $9.80M 0.88%
0.88%
New
34 183.88K $9.67M 0.87%
0.87%
New
35 80.42K $7.61M 0.68%
0.68%
New
36 40.78K $7.57M 0.68%
0.68%
Reduce
37 48.44K $6.21M 0.56%
0.56%
Add
38 770.04K $5.63M 0.50%
0.50%
Add
39 1.78M $4.98M 0.45%
0.45%
Add
40 732.26K $4.69M 0.42%
0.42%
Reduce
41 344.97K $4.53M 0.41%
0.41%
Reduce
42 7.24K $3.99M 0.36%
0.36%
Reduce
43 84.71K $3.56M 0.32%
0.32%
Reduce
44 244.26K $3.49M 0.31%
0.31%
Reduce
45 1.97M $2.74M 0.25%
0.25%
Reduce
46 174.33K $2.43M 0.22%
0.22%
Reduce
47 434.13K $1.94M 0.17%
0.17%
New
48 1.36M $1.71M 0.15%
0.15%
Reduce
49 30.80K $1.63M 0.15%
0.15%
New
50 12.82K $1.61M 0.14%
0.14%
New

FAQ

What did PFM Health Sciences, LP buy in 2025-Q2?

In its 2025-Q2 13F filing, PFM Health Sciences, LP reported 55 equity positions worth $1.12B in aggregate; its largest disclosed positions were LLY ($208.93M), THC ($87.87M), MCK ($52.99M).

How large is PFM Health Sciences, LP's portfolio?

PFM Health Sciences, LP reported $1.12B of long equity holdings across 55 positions as of 2025-Q2. Top-10 holdings account for 55.8% of reported value.

What is PFM Health Sciences, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/pfm-health-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →